Lipocine, Inc. (LPCN) Announces Phase 2b Study Results for LPCN 1111
Lipocine, Inc. (NASDAQ: LPCN) reported positive top-line results from a Phase 2b clinical study its novel oral testosterone replacement therapy ("TRT") product candidate. Named LPCN 1111, this prodrug is believed to have met the primary objectives of demonstrating the Phase 3 Dose as well as safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males. Notably, the prodrug was well tolerated with no drug-related severe or serious adverse events reported. To view the full press release, visit: http://nnw.fm/xY8YL About Lipocine Lipocine is a specialty pharmaceutical company focused on developing innovative…







